BUSINESSQUARTZ
AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
AstraZeneca stock declined following reports of merger discussions with Bristol Myers Squibb. The potential merger could create a company valued at nearly $400 billion, according to the Financial Times.
Related Signal
Adjacent reporting
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca said to have explored Bristol Myers merger